Selecta biosciences, inc (SELB)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15
Grant and collaboration revenue

6,667

6,677

926

926

913

903

27

53

0

-

0

0

-

-

-

-

-

-

-

Grant and collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

6,132

-

6,760

6,948

0

0

0

Operating expenses:
Research and development

50,114

42,743

37,847

41,628

43,901

47,687

51,054

48,673

45,260

45,165

42,575

39,092

34,098

29,702

24,152

23,445

0

0

0

General and administrative

15,974

16,389

17,463

17,829

18,077

18,238

18,763

19,084

19,625

18,826

18,912

17,030

14,545

13,051

9,489

9,232

0

0

0

Total operating expenses

66,088

59,132

55,310

59,457

61,978

65,925

69,817

67,757

64,885

63,991

61,487

56,122

48,643

42,753

33,641

32,677

0

0

0

Loss from operations

-59,421

-52,455

-54,384

-58,531

-61,065

-65,022

-69,800

-67,713

-64,815

-63,784

-58,367

-51,981

-42,511

-34,670

-26,881

-25,729

0

0

0

Investment income

797

834

928

1,039

1,039

1,050

1,067

937

792

617

492

425

334

234

146

110

0

0

0

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

Foreign currency transaction (loss), net

65

-47

-10

9

103

120

87

31

29

-123

-209

-230

-470

-525

239

44

0

0

0

Interest expense

1,396

1,519

1,579

1,575

1,540

1,494

1,458

1,342

1,256

1,206

1,169

1,212

1,243

1,253

1,265

1,284

0

0

0

Change in fair value of warrant liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other (expense), net

-1,238

-1,306

-68

-62

-59

10

-5

-8

0

-

0

0

-

4

-91

0

0

0

-

Net loss

-62,896

-55,350

-55,113

-59,120

-61,522

-65,336

-70,229

-68,904

-66,075

-65,321

-59,860

-52,912

-43,868

-36,210

-27,852

-26,991

0

0

0

Stock‑based compensation expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Temporary Equity, Accretion to Redemption Value, Adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

4,566

0

0

0

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net Income (Loss) Available to Common Stockholders, Basic

-

-

-55,113

-59,120

-

-

0

0

0

-

-

-

-46,078

-40,776

-34,254

-34,955

0

0

0

Other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss

-62,896

-55,350

-55,113

-59,120

-61,522

-65,336

-70,229

-68,904

-66,075

-65,321

-59,860

-52,912

-43,868

-36,210

-27,852

-26,991

0

0

0

Other comprehensive loss:
Foreign currency translation adjustment

-48

34

-16

-53

-150

-153

-114

-73

-26

78

167

183

396

504

-384

-154

0

0

0

Unrealized gain on securities

-2

0

0

4

15

16

6

10

8

20

-22

-11

-21

-36

16

0

0

0

-

Total comprehensive loss

-62,946

-55,316

-55,129

-59,169

-61,657

-65,473

-70,337

-68,967

-66,093

-65,223

-59,715

-52,740

-43,493

-35,742

-28,220

-27,145

0

0

0

Net loss per share:
Net loss per share attributable to common stockholders—basic and diluted (in dollars per share)

-0.21

-0.28

-0.26

-0.37

-0.31

-0.66

-0.71

-0.84

-0.71

-0.87

-0.66

-0.85

-0.82

3.81

-0.43

-2.75

-4.52

-3.50

-3.93

Weighted average common shares outstanding:
Basic and diluted (in shares)

94,723

52,483

46,407

44,855

38,447

22,452

22,403

22,355

22,345

22,329

22,082

18,814

18,474

18,370

18,108

3,322

2,175

2,159

2,147